FOX40 News

Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery

SOUTHLAKE, Texas, Jan. 9, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic ...
Seeking Alpha

Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac ...

SOUTHLAKE, Texas, April 24, 2025 /PRNewswire/ -- Renibus Therapeutics ® ("Renibus"), a clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and ...
Healio

Postoperative pulmonary complications similar with high vs. low PEEP level

The proportion of patients with postoperative pulmonary complications in the first 5 days after thoracic surgery did not ...
KHON2

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

SOUTHLAKE, Texas, Oct. 25, 2023 /PRNewswire/ -- Renibus Therapeutics ® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic ...